Skip to main content
Premium Trial:

Request an Annual Quote

NeoGenomics Completes Clarient Acquisition

NEW YORK (GenomeWeb) – NeoGenomics announced today it has completed its acquisition of Clarient from GE Healthcare's Life Sciences business.

The deal, which the cancer genetics testing provider first announced in October, has a purchase price of $80 million in cash, $110 million in preferred stock, and 15 million shares of NeoGenomics common stock, the company said in a statement. With the closing of the transaction, GE Healthcare now owns 32 percent of NeoGenomics. The company's board will also expand to include a new director from GE Healthcare, NeoGenomics added.

"We are very pleased to… begin to add Clarient's outstanding capabilities to our strong service offering," said NeoGenomics Chairman and CEO Douglas VanOort in a statement. "Clearly, the acquisition of Clarient is a major step forward in achieving our vision to become America's premier cancer testing laboratory."

Clarient, which is based in California and Texas, has about 415 employees and reported revenue of approximately $127 million in 2014, NeoGenomics said.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.